
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BBIO · as of Jun 8, 2026
Key Statistics
Explore BridgeBio Pharma, Inc. Data
bbio stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 26 · Buy rate: 92.3%
The BBIO analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $105.21, representing +55.61% upside from the current price of $67.61.
Competitors & Peers
bbio competitorsStock Performance
Full HistoryAbout BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candida…
what is bridgebio pharma, inc. · bbio stock overview · bridgebio pharma, inc. company profile · who is bridgebio pharma, inc. ceo · bbio NASDAQ · bridgebio pharma, inc. headquarters · bridgebio pharma, inc. business segments
About Stock Overview & Key Data
BridgeBio Pharma, Inc. (BBIO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 27, 2019. As of the latest trading session, BBIO stock price is $67.61, with a market capitalization of $13.2B. The stock has returned +73.23% over the past 12 months and -11.61% year-to-date.
According to 26 Wall Street analysts, the consensus rating for BridgeBio Pharma, Inc. stock is Buy, with an average 12-month price target of $105.21. In fiscal year 2025, BridgeBio Pharma, Inc. reported revenue of $502.1M and net income of -$729.3M. For detailed data — including BridgeBio Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BridgeBio Pharma, Inc. (BBIO) stock price is $67.61. The stock is traded on NASDAQ under the ticker symbol BBIO. The 52-week range is $37.69 – $84.94.